Key result
Novel therapies targeting APOC3 and ANGPTL3 robustly decrease triglyceride levels in severe hypertriglyceridemia, though definitive reduction in acute pancreatitis risk remains unproven.
Why the study?
Severe hypertriglyceridemia is difficult to treat, and traditional pharmacological agents have limited success in robustly decreasing triglyceride levels or reducing acute pancreatitis.
Do novel pharmacological agents (ASO and siRNA targeting APOC3 and ANGPTL3) reduce triglyceride levels and the risk of acute pancreatitis in patients with severe hypertriglyceridemia?
Do novel pharmacological agents (ASO and siRNA targeting APOC3 and ANGPTL3) reduce triglyceride levels and the risk of acute pancreatitis in patients with severe hypertriglyceridemia?
While novel RNA-targeted therapies offer promising triglyceride-lowering efficacy for severe hypertriglyceridemia, definitive evidence for reducing acute pancreatitis risk remains lacking.
No takes yet. Share an insight, caveat, or question.
Should not yet change practice in severe hypertriglyceridemia; leaves open whether APOC3/ANGPTL3 inhibition reduces pancreatitis risk.
Gouni‐Berthold et al. (2023) conducted a review in Severe hypertriglyceridemia. APOC3 and ANGPTL3 inhibitors was evaluated. Novel therapies targeting APOC3 and ANGPTL3 robustly decrease triglyceride levels in severe hypertriglyceridemia, though definitive reduction in acute pancreatitis risk remains unproven.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: